Expression patterns of costimulatory molecules on cells derived from human hematological malignancies

Journal of Experimental and Clinical Cancer Research

Volumn 17, Issue 3, 1998, Pages 251-258

  Zheng, Z ^a   Takahashi, M ^b   Aoki, S ^a   Toba, K ^a   Liu, A ^a   Osman, Y ^a   Takahashi, H ^a   Tsukada, N ^a   Suzuki, N ^a   Nikkuni, K ^a   Furukawa, T ^b   Koike, T ^b   Aizawa, Y ^a  

^a NIIGATA UNIVERSITY   (Japan)

^b NIIGATA UNIVERSITY   (Japan)

Author keywords

CD80; CD86; Costimulatory molecules; Cytokines; Immunogene therapy

Indexed keywords

B7 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; CELL ADHESION MOLECULE; CYTOKINE; GAMMA INTERFERON; HLA DR ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 12; INTERLEUKIN 15; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; BLAST CELL CRISIS; BURKITT LYMPHOMA; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; FOLLICULAR LYMPHOMA; GENE THERAPY; HEMATOLOGIC DISEASE; HUMAN; HUMAN CELL; IMMUNOTHERAPY; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; T CELL LEUKEMIA; TUMOR CELL LINE;

ADULT; ANTIGENS, CD; BLAST CRISIS; BURKITT LYMPHOMA; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELLS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA-DR ANTIGENS; HUMANS; INTERFERON TYPE II; INTERLEUKIN-12; INTERLEUKIN-15; LEUKEMIA, MYELOCYTIC, ACUTE; LEUKEMIA, MYELOID, CHRONIC; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; LEUKEMIA, PROMYELOCYTIC, ACUTE; LEUKEMIA, T-CELL, ACUTE; LYMPHOMA, FOLLICULAR; MYELODYSPLASTIC SYNDROMES; TUMOR CELLS, CULTURED;

EID: 0032464405     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Weaver C.T., Unaune E.R The costimulatory function of antigen-presenting cells. Immunol. Today 11:49-55, 1990.
2. Freedman A.S., Fredman G, Horowitz J.C., et al.: B7, a B-cell-restricted antigen that identifies pre-activated B cells. J. Immunol. 139: 3260-3267, 1987.
3. Linsley P.S., Lebetter J.A.: The role of the CD28 receptor during T cell responses to antigen. Annu Rev Immunol 11: 191-212, 1993.
4. June C.H., Bluestone J.A., Nadler L.M., et al.: The B7 and CD28 receptor families. Immunol. Today 15:321-331, 1994.
5. Hellstrom K.E., Hellstrom I., Chen L., et al.: Can co-stimulated tumor immunity be therapeutically efficacious? Immunol. Rev. 145: 123-145, 1995.
6. Townsend S E., Allision J.P.: Tumor rejection after direct costimulation of CD80+T cell by B7-transfected melanoma cells. Science 259: 368-370, 1993.
7. Baskar S, Glimcher L., Nabavi N., et al.: Major histocompatibility complex class II+B7-1+tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J. Exp. Med. 181: 619-629, 1995.
8. Matulonis U.A., Dosiou C., Lamont C., et al.: Rule of B7-1 inmediating an immune response to myeloid leukemia cells. Blood 85: 2507-2515, 1995.
9. Yang G., Hellstrom K.E., Hellstrom I., et al.: Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules. J. Immunol. 154: 2794-2800, 1995.
10. Chen L, McGowan P., Ashe S., et al.: Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J. Exp. Med. 79: 523-532, 1994.
11. Chen L., McGowan P, Ashe S., et al.: B7-1/CD80-transduced tumor cells elicit better systemic immunity than wild-type tumor cells admixed with cornebacterium parvum. Cancer Res. 54: 5420-5423, 1994.
12. Hirano N., Takahashi T., Takahashi T., et al.: Expression of costimulatory molecules in human leukemias. Leukemia 10: 1168-1176, 1996.
13. Komata T., Tanaka R., Yamamoto K., et al: B7-1(CD80)-transfected human glioma cells and interleukin-12 directly stimulate allogeneic CD80+T cells. J Immunotherapy 20: 256-264, 1997.
14. Grabstein K.H., Eisenman J., Shanebeck K, et al: Cloning of a T cell growth factor that interacts with the B chain of the interleukin-2 receptor. Science 264: 965-968, 1994.
15. Toba K, Koike T., Takahashi M., et al.: Characterization and sensitivity to interleukin 2 and interferon-a of leukemia cells from a patient with large granular lymphocytic leukemia associated with chronic active Epstein-Barr virus infection. Leukemia Research. 21: 941-950, 1997.
16. Gimmi C.D., Freeman G.J., Gribben J.G., et al.: B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2. Proc. Natl. Acad. Sci. USA 88: 6575-6579, 1991.
17. Linsey P.S., Brady W., Grosmaire L., et al.: Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J. Exp. Med. 173: 721-730, 1991.
18. Koulova L., Clark E.A., Shu G., et al.: The CD28 ligand B7/BB 1 provides costimulatory signal for alloactivation of CD4+T cells. J. Exp Med. 173: 759-762, 1991.
19. June C. H., Bluestone JA, Nadler L.M., et al.: The B7 and CD28 receptor families. Immunol. Today 15: 321-331, 1994
20. Chen C., Nabavi N.: In vitro induction of T cell anergy by blocking B7 and early T cell costimulatory molecule ETC-1/B7-2. Immunity 1: 147-154, 1994.
21. Freeman G.J., Freedman A.S., Segil J.M., et al.: B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells. J. Immunol. 143: 2714-2722, 1989.
22. Freedman A.S.: Expression and function of adhesion receptors on normal B cells and B cell non-Hodgkin's lymphomas. Semin. Hematol. 30: 318-328, 1993.
23. Tsukada N., Aoki S., Maruyama S., et al.: The heterogeneous expression of CD80, CD86 and other adhesion molecules on leukemia and lymphoma cells and their induction by interferon. J. Exp Cancer Res. 16: 171-176, 1997.
24. Walunas T.L., Lenschow D.J., Bakker C.Y. et al.: CTLA4 can function as a negative regulator of T cell activation. Immunity 1: 405-413, 1994
25. Leach D.R., Krummel M.F., Allson J.P., et al.: Enhancement of antitumor immunity by CTLA-4 blockade. Science 271: 1734-1736, 1996.
26. Cardoso A.A., Schultze J.L., Boussiotis V.A., et al.: Pre-B acute lymphoblastic leukemia cell may induce T-cell anergy. Blood 88: 41-48, 1996.
27. Boussiotis V.A., Freeman G.J., Griffin J.D., et al.: CD2 is involved in maintenance and reversal of human alloantigen-specific colonel anergy. J. Exp. Med. 180: 1665-1673, 1994.
28. Boussiotis V.A., Freeman G.J., Griffin J.D., et al.: The critical role of CD28 signaling in prevention of human T-cell anergy. Res. Immunol. 146: 140-149, 1995.
29. Kuchroo V.K., Das M.P., Brown J.A., et al.: B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathway: application to autoimmune disease therapy. Cell 80: 707-718, 1995.
30. Zitvogel L., Robbins P.D., Storkus W.J., et al.:Interleukin-12 and B7.1 costimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors. Eur. J. Immunol.26: 1335-1341, 1996.
31. Carson W.E, Gin J.G., Lindemann M.J., et al.: Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J. Exp. Med. 180: 1395-1403, 1994.
32. Nishimura H., Hiromatsu K., Kobayashi N., et al: IL-15 is a novel growth factor for murine γδ Tcells by Salmonella infection. J. Immunol. 156: 663-669, 1996.
33. Grabstein K.H., Eisenman J., Shanebeck K., et al.: Cloning of a T cell growth factor that interacts with the chain of the interleukin-2 receptor. Science 264: 965-968, 1994.
34. Armitago R.J., Macduff B.M., Eisenman J., et al: IL-15 has stimulatory activity for the induction of B cell proliferation and differentiation. J. Immunol. 154: 483-490, 1995.
35. Pericle F., Epling-Burnette P.K., Podack E.R., et al: CD40 CD40L interaction provide "third-party" costimulation for T cell response against B7-1-transfected human breast tumor cells. J. Leukocyte Biol.61:201-208, 1997.
36. Cavallo F., Martin F.A., Bellone M., et al: Co-expression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response. Eur. J. Immunol. 25: 1154-1162, 1995.